Zentalis Pharmaceuticals (ZNTL) Income towards Parent Company (2019 - 2026)
Zentalis Pharmaceuticals (ZNTL) posted quarterly Income towards Parent Company of -$35.4 million for Q1 2026, up 26.78% year-over-year from -$27.9 million in Q1 2025, and little changed quarter-over-quarter from -$35.2 million in Q4 2025.
Zentalis Pharmaceuticals (ZNTL) Income towards Parent Company (2019 - 2026) Analysis & Trends
Zentalis Pharmaceuticals' Income towards Parent Company history runs 8 years deep, the most recent figure standing at -$35.4 million for Q1 2026.
- In Q1 2026, Income towards Parent Company rose 26.78% year-over-year to -$35.4 million; the TTM figure through Mar 2026 stood at -$124.1 million (up 44.63% YoY), while the FY2025 annual figure was -$137.1 million, up 17.37% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$35.4 million, roughly flat from -$35.2 million in the prior quarter.
- The five-year high for Income towards Parent Company was $10.0 million in Q1 2024, with the low at -$98.9 million in Q2 2023.
- The 5-year median for Income towards Parent Company is -$48.3 million (2025), against an average of -$49.1 million.
- The sharpest annual moves came in 2024 and 2025: Income towards Parent Company jumped 116.47% in 2024, then slumped 580.87% in 2025.
- Zentalis Pharmaceuticals' Income towards Parent Company stood at -$48.2 million in 2022, then retreated by 26.53% to -$60.9 million in 2023, then rose by 22.1% to -$47.5 million in 2024, then increased by 25.82% to -$35.2 million in 2025, then dropped by 0.39% to -$35.4 million in 2026.
- Business Quant data shows ZNTL's Income towards Parent Company at -$35.4 million in Q1 2026, -$35.2 million in Q4 2025, and -$26.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Zentalis Pharmaceuticals | 255.14 Mn | 255.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -42.29 Mn |
| Mar 31, 2026 | -35.35 Mn |
| Dec 31, 2025 | -35.22 Mn |
| Sep 30, 2025 | -26.69 Mn |
| Jun 30, 2025 | -26.87 Mn |
| Mar 31, 2025 | -48.28 Mn |
| Dec 31, 2024 | -47.47 Mn |
| Sep 30, 2024 | -40.16 Mn |
| Jun 30, 2024 | -88.28 Mn |
| Mar 31, 2024 | 10.04 Mn |
| Dec 31, 2023 | -60.94 Mn |
| Sep 30, 2023 | -55.54 Mn |
| Jun 30, 2023 | -98.86 Mn |
| Mar 31, 2023 | -60.95 Mn |
| Dec 31, 2022 | -48.16 Mn |
| Sep 30, 2022 | -52.13 Mn |
| Jun 30, 2022 | -63.05 Mn |
| Mar 31, 2022 | -57.49 Mn |
| Dec 31, 2021 | -48.26 Mn |
| Sep 30, 2021 | -10.49 Mn |